HCA Healthcare, Inc. (HCA) Form 8-K — Oct 27, 2026
HCA Healthcare reported Q3 2026 revenue of $19.849 billion, up 3.6% year-over-year, with diluted EPS up 4.5% to $7.27 and Adjusted EBITDA up 1.2% to $3.918 billion. Net income declined 3.9% to $1.579 billion as an estimated $400 million unfavorable payer mix shift from patients losing health insurance exchange coverage pressured pretax income. The company raised its full-year 2026 outlook to the upper half of prior guidance ranges, with revenue of $77.0-$79.5 billion, Adjusted EBITDA of $15.4-$16.1 billion, and diluted EPS of $28.70-$30.50. Same facility equivalent admissions accelerated to +3.0% growth and ER visits rose 5.1%.
Key figures
- Eps
- 7.27
- Revenue
- 19849000000
- Guidance
- Full year 2026 results now expected in the upper half of prior guidance ranges issued July 14, 2026; FY2026 revenue $77.0-79.5B, Adjusted EBITDA $15.4-16.1B, diluted EPS $28.70-30.50
- Net Income
- 1579000000
- Total Debt
- 50493000000
- Revenue Yoy
- 3.6%
- Total Assets
- 63452000000
- Cash Position
- 908000000
- Shares Outstanding
- 217.212 million diluted shares in Q3 2026
- Adjusted eps
- 7.22
- Adjusted ebitda q3
- 3918000000
- Hospitals operated
- 189
- Adjusted ebitda yoy
- 1.2%
- Share repurchases q3
- $2.970 billion for 7.230 million shares
- Dividend payment date
- December 29, 2026
- Operating cash flow q3
- 4461000000
- Payer mix headwind pretax
- 400000000
- Quarterly dividend per share
- 0.78
- Buyback authorization remaining
- 4240000000
- Same facility admissions growth
- 2.7%
- Same facility equivalent admissions growth
- 3.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.